On-Demand CME Videos

Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Stop the Itch that Rashes: Online CME Activity

About

This activity was recorded at the 2022 Fall Clinical Dermatology Conference on October 22, 2022.

CME Satellite Symposium: Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Stop the Itch that Rashes


This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals. 

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

November 15, 2022

Expiration Date:

November 15, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Overview the key data on systemic biologics for the management of moderate-to-severe atopic dermatitis in children and adolescents

  • Identify children and adolescents who would benefit from biologics for the management of moderate-to-severe atopic dermatitis

  • Describe strategies to integrate biologics into daily clinical practice to effectively manage moderate-to-severe AD

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Benjamin
Benjamin Lockshin, MD

EVP of Strategic Initiatives
Director of the Clinical Trials Center
Assistant Professor
US Dermatology Partners
Georgetown University
Rockville, MD

Mona
Mona Shahriari, MD

Dermatologist
Central CT Dermatology
Cromwell, CT

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Benjamin Lockshin, MD

Grant/Research Support: Abbvie, Eli Lilly, Celgene, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Pfizer, Leo, Arcutis, Dermavant 

Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Dermavant, Arcutis, Leo 

Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly, Regeneron, Sanofi Genzyme, Dermavant, Arcutis, Leo

Mona Shahriari, MD

Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union

Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB

Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved